The Road to Zero: Scaling the Fight Against Viral Hepatitis
The global landscape of viral hepatitis is shifting. While the World Health Organization (WHO) has documented measurable progress in reducing infections and deaths, the scale of the challenge remains immense. With 287 million people living with chronic hepatitis B or C, the transition from “managing” the disease to “eliminating” it requires a fundamental shift in how healthcare systems operate.
The path forward isn’t about discovering new miracles—the tools already exist. Instead, the future of hepatitis elimination depends on closing the gap between medical capability and patient access.
Closing the Treatment Gap: From Specialized Clinics to Primary Care
One of the most significant trends in the fight against viral hepatitis is the push for decentralization. For too long, hepatitis care has been locked behind the doors of specialist clinics, creating barriers for the most vulnerable populations.
Dr. Tereza Kasaeva, Director of the WHO Department for HIV, TB, Hepatitis and Sexually Transmitted Infections, emphasizes that countries must move faster to integrate hepatitis services into primary care. By moving screening and treatment into community clinics, healthcare providers can reach those who are currently undiagnosed due to stigma or weak health systems.
This shift is critical for hepatitis B, where the treatment gap is staggering. Currently, fewer than 5% of the 240 million people with chronic hepatitis B are receiving the long-term antiviral treatment necessary to prevent severe liver disease.
The Blueprint for Success: Learning from Global Leaders
Elimination is not a theoretical goal; We see a proven reality in specific regions. Countries such as Egypt, Georgia, Rwanda, and the United Kingdom have demonstrated that sustained investment and political commitment can drastically reduce the public health threat of hepatitis.
These nations provide a roadmap for others, proving that when political will is backed by reliable domestic financing, the targets set by the World Health Assembly become achievable.
Targeting High-Burden Regions and Vulnerable Groups
Future progress will not be uniform; it must be targeted. The global burden of hepatitis is heavily concentrated, meaning strategic interventions in a few key areas can lead to massive global gains.
Prioritizing the WHO African and Western Pacific Regions
Hepatitis B remains a primary concern in these regions. In the WHO African Region, 68% of new hepatitis B infections occur, yet only 17% of newborns receive the essential hepatitis B birth-dose vaccination. Expanding this vaccine coverage and improving antiviral prophylaxis to prevent mother-to-child transmission are top priorities for reducing the next generation’s disease burden.
Addressing the Harm Reduction Crisis
For hepatitis C, the trend is closely tied to social determinants of health. People who inject drugs accounted for 44% of new infections in 2024. This underscores an urgent require for:
- Strengthened harm reduction services.
- Safe injection practices in both community and healthcare settings.
- Low-barrier access to curative short-course therapies.
Preventing the Silent Killers: Cirrhosis and Cancer
The ultimate goal of accelerating diagnosis is to prevent the most devastating outcomes: liver cirrhosis and hepatocellular carcinoma. These are the primary drivers of hepatitis-related deaths, which claimed 1.34 million lives in 2024 alone.
The burden is particularly high in ten countries—including Bangladesh, China, Ethiopia, Ghana, India, Indonesia, Nigeria, the Philippines, South Africa, and Viet Nam—which together accounted for 69% of hepatitis B-related deaths. By scaling up testing in these specific geographies, the global community can prevent hundreds of thousands of avoidable deaths.
As WHO Director-General Dr. Tedros Adhanom Ghebreyesus noted, “Every missed diagnosis and untreated infection due to chronic viral hepatitis represents a preventable death.”
Frequently Asked Questions
What is the difference between Hepatitis B and C treatment?
Hepatitis B is managed with long-term antiviral treatment to control the infection and prevent liver damage. Hepatitis C can be cured entirely with a short-course curative therapy lasting 8-12 weeks.
Why is the birth-dose vaccine so important?
The hepatitis B vaccine protects more than 95% of vaccinated people against both acute and chronic infections. Administering it at birth is the most effective way to prevent mother-to-child transmission.
Which regions are most affected by viral hepatitis?
The WHO African and Western Pacific regions face the highest burden of hepatitis B, while the Eastern Mediterranean Region is a priority for expanding hepatitis C treatment access.
Join the Conversation: Do you think primary healthcare integration is the key to eliminating viral hepatitis, or should the focus remain on specialized centers of excellence? Share your thoughts in the comments below or subscribe to our newsletter for more deep dives into global health trends.
For more information on global health targets, visit the World Health Organization official portal.
